SLU-PP-332 vs Syn-Ake
Side-by-side comparison of key properties, dosing, and research.
Recovery & RepairFat Loss & Metabolic
SLU-PP-332Skin & CosmeticAnti-Aging & Longevity
Syn-Ake- Summary
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Syn-Ake is a synthetic tripeptide that mimics waglerin-1, a peptide found in the venom of the Temple viper (Tropidolaemus wagleri). It acts as a reversible antagonist of muscular nicotinic acetylcholine receptors, temporarily reducing facial muscle contraction and smoothing dynamic wrinkles. Often called a 'synthetic Botox' in cosmetic marketing.
- Half-Life
- Not established in humans; rodent pharmacokinetics suggest hours
- Not applicable (topical; effect duration hours)
- Admin Route
- Oral (research), Subcutaneous (research)
- Topical
- Research
- —
- —
- Typical Dose
- Not established for humans; rodent studies used ~100 mg/kg/day
- 0.01–0.1% (4–8 mg/g in clinical studies)
- Frequency
- Once daily in rodent studies
- Twice daily
- Key Benefits
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Reduces depth of dynamic wrinkles and expression lines
- Reversible muscle-relaxing effect on facial muscles
- Smooths forehead lines, crow's feet, and frown lines
- Non-invasive alternative to injectable neurotoxins
- Rapid onset relative to collagen-stimulating peptides
- Well-studied in in vitro and clinical cosmetic trials
- Side Effects
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Generally very well-tolerated topically
- Rare skin sensitivity or contact dermatitis
- Theoretical neuromuscular effects at systemic doses (not relevant topically)
- Stacks With
- —
- —